PRODUCT DETAILS VIEW ALL PRODUCTS

Micropenam S Injection (Meropenem + Salbactum)

  • Each vial contains: Meropenem trihydrate IP equivalent to anhydrous meropenem 1g, Sulbactam Sodium USP equivalent to Sulbactam 0.5 gm.
  • Indicated for the treatment of lower respiratory tract infection caused by gram negative bacteria in adults only.
  • Meropenem is a broad-spectrum carbapenem antibiotic. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa and PBPs 1, 2, and 4 of Staphylococcus aureus. Sulbactam is a synthetic beta-lactamase inhibitor. A feature that distinguishes sulbactam from other available beta-lactamase inhibitors is its direct antimicrobial activity against the Acinetobacter species and Bacteriodes fragilis.
  • IV bolus injection over approximately five minutes, or by IV infusion over approximately 15-30 minutes, using the specific available diluents, every eight hours.
  • If an allergic reaction occurs, the drug should be discontinued and the appropriate therapy instituted. Seizures and other CNS experiences have been reported during treatment. Co-administration of Meropenem with valproic acid or divalproex sodium reduces the serum concentration of valproic acid potentially increasing the risk of breakthrough seizures. Clostridium difficle-asssociated diarrhoea has been reported. Patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem.
  • Pregnancy Category B. has been reported to be excreted in human milk. Caution should be exercised when meropenem is administered to a nursing woman. The safety and effectiveness of meropenem have been established for paediatric patients 3 months of age and older with complicated skin and skin structure infections and bacterial meningitis, and for paediatric patients of all ages with complicated intra-abdominal infections.
  • The co-administration of probenecid with meropenem I.V. is not recommended. If administration of meropenem I.V. is necessary, then supplemental anti-convulsant therapy should be considered.
  • Inflammation at the injection site, thrombophlebitis, injection site reaction, pain at the injection site, and oedema at the injection site. diarrhoea, nausea/vomiting, headache, rash, sepsis, constipation, apnoea, shock and pruritus.
  • Anti-Bacterials